Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

1.07

Mkt cap

1.8M

Volume

93K

High

1.08

P/E Ratio

-0.62

52-wk high

18.36

Low

0.94

Div yield

N/A

52-wk low

0.70

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) will present a scientific poster on the long-term safety data of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting. The company will also review the use of 8-aminoquinolines in treating malaria and babesiosis. Tafenoquine is approved for malaria prophylaxis in the US under the product name ARAKODA®. However, it has not been proven effective for treatment or prevention of babesiosis and is not FDA approved for such indications.

Portfolio Pulse from Happy Mohamed

October 19, 2023 | 12:42 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. Bio-Path Hldgs, Comera Life Sciences, Scinai Immunotherapeutics, 60 Degrees, Bellerophon Therapeutics, and Relay Therapeutics saw increases, while Cassava Sciences, Outset Medical, T2 Biosystems, OpGen, Tempest Therapeutics, and BeyondSpring saw decreases.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 9:32 pm

60 Degrees Pharmaceuticals has suspended its Phase IIB study of tafenoquine for COVID-19, following FDA advice that the study may not be feasible in the U.S. The company will now focus on commercializing treatments for malaria and tick-borne diseases, including a Phase IIA study of tafenoquine in hospitalized babesiosis patients. A pre-IND meeting request with the FDA for babesiosis is planned for Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:18 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Acorda Therapeutics (ACOR), Vivos Therapeutics (VVOS), Pasithea Therapeutics (KTTA), Enveric Biosciences (ENVB), 60 Degrees (SXTP), and Esperion Therapeutics (ESPR). Losers included MaxCyte (MXCT), Heart Test Laboratories (HSCS), Senti Biosciences (SNTI), Accolade (ACCD), Elutia (ELUT), and PDS Biotechnology (PDSB).

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 9:31 pm

Ascendiant Capital analyst Lucas Ward has initiated coverage on 60 Degrees (NASDAQ:SXTP) with a Buy rating and a price target of $2.4.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:22 am

US stocks traded lower with the Dow Jones falling more than 150 points. AutoZone Inc reported better-than-expected earnings for its fourth quarter. Rackspace Technology, Avinger, and Elutia Inc shares shot up after positive news. 60 Degrees Pharmaceuticals, Histogen Inc, and Revance Therapeutics shares dropped due to negative developments. The FOMC starts its two-day policy meeting today.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 6:32 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Longeveron Inc., Avinger, Navidea Biopharmaceutical, Elutia, ABVC BioPharma, and Akili saw increases in their shares, with Longeveron Inc. leading with a 172.7% increase. On the other hand, UpHealth, 60 Degrees, T2 Biosystems, SCWorx, Kinnate Biopharma, and MSP Recovery saw decreases in their shares, with UpHealth experiencing the largest decline of 50%.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 1:06 pm

60 Degrees Pharmaceuticals Inc's subsidiary, 60P Australia Pty Ltd, has withdrawn its investigational new drug application for ACLR8-LR, a Phase 2B study of the use of tafenoquine in treating COVID-19, in response to FDA comments. The company plans to submit a new application in Q4, pending a feasibility assessment of revising the trial design. Meanwhile, 60P has paused further start-up activities for its Phase 2B trial, improving its short-term cash position. The company's shares are down 28.1% in premarket trading.

Portfolio Pulse from Vandana Singh

September 19, 2023 | 1:04 pm

Shares of several companies including Connexa Sports Technologies, Elutia, Galera Therapeutics, Senti Biosciences, Neptune Wellness Solutions, Aclarion, Cybin, Avinger, SelectQuote, and Bit Brother Limited are trading higher in pre-market. Elutia's shares rose after the sale of its Orthobiologics business unit to Berkeley Biologics. Galera scheduled a meeting with the FDA to discuss next steps for its radiotherapy avasopasem. Neptune Wellness announced intention to spinout Sprout Organics. Cybin shares surged after hedge fund owner Steve Cohen invested $19 million in the company. On the other hand, shares of Digital Transformation Opportunities Corp., Rocket Lab USA, Novo Integrated Sciences, 60 Degrees Pharmaceuticals, Terran Orbital Corporation, Perspective Therapeutics, MSP Recovery, T2 Biosystems, SCWorx Corp., and FLJ Group Limited are trading lower in pre-market.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 11:59 am

60 Degrees Pharma has withdrawn its Covid Phase 2B Investigational New Drug, with plans to resubmit after assessing its ability to meet FDA requirements. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.